Dexcom (DXCM) Stock
Continuous glucose monitoring systems provider for diabetes. Here's the price, business snapshot, and what's worth knowing about Dexcom in August 2026.
DexCom, Inc. (DXCM) designs and sells continuous glucose monitoring (CGM) systems used by people with diabetes and healthcare providers. Its product suite—sensors, transmitters and supporting software—aims to provide real‑time glucose readings and trend data, with recurring revenue from consumable sensors and subscription services. Key positives include strong adoption in type 1 diabetes, a growing addressable market among type 2 patients, ongoing product upgrades (including smaller form factors) and partnerships with insulin‑delivery firms. Risks include competitive pressure (from established medical device makers and newer entrants), reimbursement and regulatory outcomes across markets, supply chain constraints and the potential for device recalls or pricing pressure. With a market capitalisation around $27.4bn, DexCom is often viewed as a growth‑oriented medical device company; investors should weigh revenue visibility from consumables against execution and regulatory risks. This is general information only, not personalised investment advice; returns are not guaranteed and share values can fall as well as rise.
Why It’s Moving
DexCom is still catching a bid as earnings momentum and product expansion keep fueling the rally.
- DexCom shares have been building on a late-July earnings beat, where revenue came in above expectations and management nudged full-year 2026 guidance higher, reinforcing confidence in the company’s growth trajectory.
- Investor sentiment has also been helped by the company’s expanding footprint in continuous glucose monitoring, including broader access for Type 2 diabetes patients and next-generation sensor development, which points to a larger addressable market.
- Recent momentum has been supported by fresh institutional interest and the stock’s move to a 52-week high, suggesting traders are leaning into the stronger growth-and-margin story rather than last year’s weakness.
DexCom is still catching a bid as earnings momentum and product expansion keep fueling the rally.
- DexCom shares have been building on a late-July earnings beat, where revenue came in above expectations and management nudged full-year 2026 guidance higher, reinforcing confidence in the company’s growth trajectory.
- Investor sentiment has also been helped by the company’s expanding footprint in continuous glucose monitoring, including broader access for Type 2 diabetes patients and next-generation sensor development, which points to a larger addressable market.
- Recent momentum has been supported by fresh institutional interest and the stock’s move to a 52-week high, suggesting traders are leaning into the stronger growth-and-margin story rather than last year’s weakness.
Sixth Month Growth Performance
When is the next earnings date for DEXCOM INC (DXCM)?
DexCom’s next earnings date is estimated for October 29, 2026, based on its historical reporting pattern. The report is expected to cover Q3 2026 results. Management has not formally confirmed the date yet, so the timing remains an estimate.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Dexcom's stock with a target price of $112.8, indicating significant growth potential.
Financial Health
Dexcom is achieving strong sales and profits, with solid cash flow and healthy margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue growth
Consumable sensors and subscription services support revenue predictability, though sales can fluctuate with reimbursement and competitive dynamics.
Product innovation pipeline
Smaller sensors, improved accuracy and system integrations keep the product roadmap active, but technical or regulatory setbacks can affect adoption.
Global expansion potential
International markets present sizeable opportunity as CGM adoption rises, balanced by differing regulatory regimes and payer systems that can slow rollout.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
